

## Product datasheet for **TR303046**

### **NALP2 (NLRP2) Human shRNA Plasmid Kit (Locus ID 55655)**

#### **Product data:**

<b>Product Type:</b>	shRNA Plasmids
<b>Product Name:</b>	NALP2 (NLRP2) Human shRNA Plasmid Kit (Locus ID 55655)
<b>Locus ID:</b>	55655
<b>Synonyms:</b>	CLR19.9; NALP2; NBS1; PAN1; PYPAF2
<b>Vector:</b>	pRS (TR20003)
<b>E. coli Selection:</b>	Ampicillin
<b>Mammalian Cell Selection:</b>	Puromycin
<b>Format:</b>	Retroviral plasmids
<b>Components:</b>	NLRP2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 55655). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
<b>RefSeq:</b>	<u><a href="#">BC001039</a></u> , <u><a href="#">NM_001174081</a></u> , <u><a href="#">NM_001174082</a></u> , <u><a href="#">NM_001174083</a></u> , <u><a href="#">NM_017852</a></u> , <u><a href="#">NM_001348003</a></u> , <u><a href="#">NR_145325</a></u> , <u><a href="#">NM_017852.1</a></u> , <u><a href="#">NM_017852.2</a></u> , <u><a href="#">NM_017852.3</a></u> , <u><a href="#">NM_017852.4</a></u> , <u><a href="#">NM_001174083.1</a></u> , <u><a href="#">NM_001174082.1</a></u> , <u><a href="#">NM_001174082.2</a></u> , <u><a href="#">NM_001174081.1</a></u> , <u><a href="#">NM_001174081.2</a></u> , <u><a href="#">BC001039.2</a></u> , <u><a href="#">BC003592</a></u> , <u><a href="#">BC039269</a></u> , <u><a href="#">NM_001174083.2</a></u> , <u><a href="#">NM_001174081.3</a></u>
<b>UniProt ID:</b>	<u><a href="#">Q9NX02</a></u>
<b>Summary:</b>	This gene is a member of the nucleotide-binding and leucine-rich repeat receptor (NLR) family, and is predicted to contain an N-terminal pyrin effector domain (PYD), a centrally-located nucleotide-binding and oligomerization domain (NACHT) and C-terminal leucine-rich repeats (LRR). Members of this gene family are thought to be important regulators of immune responses. This gene product interacts with components of the IκB kinase (IKK) complex, and can regulate both caspase-1 and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activity. The pyrin domain is necessary and sufficient for suppression of NF-κB activity. An allelic variant (rs147585490) has been found that is incapable of blocking the transcriptional activity of NF-κB. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Dec 2016]
<b>shRNA Design:</b>	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).